Advertisement
Advertisement
U.S. markets open in 1 hour 56 minutes
S&P Futures
3,826.50 -7.50 (-0.20%) Dow Futures
30,892.00 -44.00 (-0.14%) Nasdaq Futures
11,776.25 -32.25 (-0.27%) Russell 2000 Futures
1,736.70 -5.00 (-0.29%) Crude Oil
100.12 +0.62 (+0.62%) Gold
1,760.30 -3.60 (-0.20%)
At close: 04:00PM EDT
Pre-Market:
Advertisement
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Performance Outlook
| Previous Close | 84.36 |
| Open | 83.61 |
| Bid | 83.55 x 1000 |
| Ask | 83.88 x 900 |
| Day's Range | 83.34 - 84.29 |
| 52 Week Range | 79.09 - 95.17 |
| Volume | |
| Avg. Volume | 2,417,976 |
| Market Cap | 186.478B |
| Beta (5Y Monthly) | 0.48 |
| PE Ratio (TTM) | 7.87 |
| EPS (TTM) | 10.71 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 3.33 (3.95%) |
| Ex-Dividend Date | Mar 08, 2022 |
| 1y Target Est | 104.40 |
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Near Fair Value
3% Est. Return
Subscribe to Yahoo Finance Plus to view Fair Value for NVS
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
- Novartis AGAnalyst Report: Novartis AGNovartis AG develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.RatingFair ValueEconomic Moat16 days agoMorningstar
- Investor's Business Daily
Celldex Therapeutics Skids As It Takes On A Blockbuster Roche, Novartis Drug
Celldex took aim at Roche and Novartis' blockbuster hives drug on Friday with a small study that showed promise — but CLDX stock tumbled.
- Zacks
Novartis (NVS) Announces Positive Data on Oncology Drug
Novartis' (NVS) anti-PD-1 monoclonal antibody, tislelizumab, significantly extends median overall survival in first-line advanced esophageal cancer combined with chemotherapy.
- Zacks
The Zacks Analyst Blog Highlights Sanofi, Merck, Novartis, Pfizer and J&J
Sanofi, Merck, Novartis, Pfizer and J&J are part of Zacks top Analyst Blog.
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
© 2022 Yahoo. All rights reserved.
